Capreomycin

CHEMBL2221250 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1321.4 g/mol

LogP

—

Phase

4

A cyclic peptide antibiotic used to treat multidrug-resistant tuberculosis, particularly when first-line drugs have failed or cannot be used. It works by inhibiting bacterial protein synthesis at the ribosomal level. It must be given by injection and requires monitoring for kidney toxicity and hearing loss.

Moleküler Ağırlık

1321,4000 g/mol

TPSA

737,00 Å²

Terapötik Alanlar

Tuberculosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1

InChI

InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9-;16-10-/t11?,12-,13?,14-,16-,18-;11-,12?,13-,14?,15-,18-/m00/s1

Molecular Formula

C50H88N28O15

HBD / HBA

27 / 23

Döndürülebilir Bağlar

19

Ağır Atomlar

93

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A cyclic peptide antibiotic used to treat multidrug-resistant tuberculosis, particularly when first-line drugs have failed or cannot be used. It works by inhibiting bacterial protein synthesis at the ribosomal level. It must be given by injection and requires monitoring for kidney toxicity and hearing loss.

Yes, Capreomycin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2221250. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3000502. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Capreomycin PillFYI'da

Yapı

Hızlı Veriler

Formül: C50H88N28O15

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.